Biotech startups are crucial to India’s future economy, says Dr Jitendra Singh

India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025

Thermo Fisher Scientific to acquire CorEvitas for $912.5 million

Advances clinical research capabilities with leading regulatory grade registries platform

Granules India successfully completes Two US FDA Audits in a span of 2 weeks

The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.

Granules India and Central Bureau of Narcotics unite to tackle drug abuse

Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society

Industry needs to establish a self-regulatory body to maintain the quality of the pharma products, says Dr Mandaviya

Eugia Pharma signs voluntary license with Medicines Patent Pool to develop generic version of Nilotinib Capsules

The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India

Fortis Healthcare to divest its Vadapalani, Chennai Hospital business operations to Kauvery Group of Hospitals

Biostar Pharma receives FDA approval Utidelone Injectable Phase 2/3 clinical trial for cell lung cancer

This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable

Merck completes acquisition of Prometheus Biosciences

Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions

Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule

UTD2 is the world's first oral epothilone microtubule inhibitor